60437-30-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-benzyl-4-hydroxypiperidine-4-carboxylate is used as a key starting material for the production of gabapentin, an anticonvulsant medication used to treat epilepsy and neuropathic pain. Its role as an intermediate in the synthesis of gabapentin makes it a crucial component in the development of this medication.
Used in Medication Production:
MBHC is used as a building block for the production of various medications. Its versatile chemical structure allows it to be incorporated into the synthesis of a range of pharmaceutical compounds, contributing to the development of new and improved treatments for various medical conditions.

Upstream product

• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 
• 67-56-1 methanol 
• 59119-18-5 1-benzyl-4-hydroxypiperidine-4-carboxylic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 495415-09-3 1-tert-butyl 4-methyl 4-hydroxypiperidine-1,4-dicarboxylate 
• 767265-77-0 methyl 4-hydroxy-4-piperidinecarboxylate 
• 26728-12-1 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-3-phenyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 343327-63-9 3-benzyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 26733-63-1 3-phenyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 49614-61-1 3-benzyl-8-[3-(2-chloro-phenothiazin-10-yl)-propyl]-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 26728-13-2 8-[3-(2-chloro-phenothiazin-10-yl)-propyl]-3-phenyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 92197-36-9 4-hydroxy-4-(hydroxymethyl)-1-(phenylmethyl)piperidine 
• 27894-41-3 8-benzyl-3-ethyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 26728-07-4 3,8-dibenzyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 26733-62-0 8-benzyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 26786-44-7 8-benzyl-3-methyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 26733-55-1 8-benzyl-3-phenyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 

Relevant academic research and scientific papers

PHENOTHIAZINE DERIVATIVES AND USES THEREOF

The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

COMPOUNDS USEFUL AS IMMUNOMODULATORS

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Anesthetic compounds and related methods of use

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES

The present invention relates to novel substituted spirotetronic acids (I) in which R1 and R2, together with the carbon atom to which they are bonded, form a group of the formula (1), (2), (3) or (4), whereby * represents the carbon

Novel amides useful for treating pain

The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I) that useful in treating pain.

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

Synthesis and Structure-Activity Studies of a Series of Spirooxazolidine-2,4-diones: 4-Oxa Analogues of the Muscarinic Agonist 2-Ethyl-8-methyl-2,8-diazaspirodecane-1,3-dione

A series of spirooxazolidine-2,4-dione derivatives related to the putative M1 agonist 2-ethyl-8-methyl-2,8-diazaspirodecane-1,3-dione (RS86; 1) were synthesized.The compounds were evaluated as cholinergic agents in in vitro binding assays and in in vivo pharmacological tests including antiamnesic effects using scopolamine-treated mice, hypothermia, and salivation in mice.Four compounds (5a,c,f and 17a) exhibited affinity for cortical M1 receptors and reversed scopolamine-induced impairment of mouse passive avoidance tasks, as did 1.Among these compounds only 5a exhibited M1-receptor stimulating activity in pithed rats.Structural requirements for muscarinic activity in this series of spirooxazolidine-2,4-dione derivatives were as strict as those reported for spirocuccinimide derivatives including 1.The antiamnesic dose of 3-ethyl-8-methyl-1-oxo-3,8-diazaspirodecane-2,4-dione (5a) was 2 orders of magnitude lower than the doses inducing hypothermia and salivation, in contrast to 1 for which the former dose was only 5-10-fold lower than the latter.These results suggest that the 8-azaspirodecane skeleton represents a useful template for designing new muscarinic agonists as antidementia drugs.